34 -6 (56) 2023 — Ubaydova D.S. — CLINICAL ASPECTS OF LIVER DAMAGE IN COVID-19

CLINICAL ASPECTS OF LIVER DAMAGE IN COVID-19

Ubaydova Dilafruz Saddikovna Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

COVID-19 poses a serious threat to global public health. Currently, COVID-19 is considered as a systemic disease with impaired immune system function, affecting primarily the lungs, but also the heart, kidneys, intestines, liver and spleen. Liver damage occurs mainly in severe COVID-19. Today, it is not entirely clear whether changes in liver laboratory parameters in patients with COVID-19 are related to previously diagnosed liver disease, or whether they reflect liver damage in COVID-19. The article presents works devoted to the study of liver lesions during the period of COVID-19 disease in patients without previous pathology or with pre-existingliverpathology.

Keywords. COVID-19, liver, SARS-CoV-2, chronic liver disease

First page

213

last page

216

For citation: Ubaydova D.S. – CLINICAL ASPECTS OF LIVER DAMAGE IN COVID-19 //New Day in Medicine 2023 6(56); 213-216 https://newdaymedicine.com/index.php/2023/06/17/l-168/

LIST OF REFERENCES:

  1. Wang D., Hu B., Hu C, et al. Clinical characteristics of 138 hospitalized patients with (2019) novel coronavirusinfected pneumonia in Wuhan, China  JAMA.  (2020) 323(11):1061-1069.
  2. Waseem N., Chen P.H. Hypoxic hepatitis a review and clinical update J Clin TranslHepatol.  (2016)  4:263-268.
  3. Xie H., Zhao J., Lian N., et al. Clinical characteristics of non-ICU hospitalized patients withcoronavirus disease (2019) and liver injury A retrospective study Liver Int.  (2020) 40:1321-1326.
  4. Yang X., Yu Y., Xu J., et al. Clinical course and outcomes of critically ill patients with SARSCoV-2 pneumonia in Wuhan, China a single-centered, retrospective, observational study  Lancet Respir Med.  (2020) 8:475-481.
  5. Yeo C., Kaushal S., Yeo D. Enteric involvement of coronaviruses is faecal-oral transmission of SARSCoV-2 possible?  Lancet Gastroenterol Hepatol.  (2020) 5:335-337.
  6. Zhang C., Shi L., Wang F.S. Liver injury in COVID-19 management and challenges Lancet Gastroenterol. Hepatol.  (2020) 5(5):428-430.
  7. Zhang J., Wang S., Xue Y. Fecal specimen diagnosis (2019) novel coronavirusinfected pneumonia  J MedVirol.  (2020) 92:680-682.  doi 10.1002/jmv.25742
  8. Ubaydova Dilafruz Saddikovna Сlinical aspects of liver damage in COVID-19 Asian journal of Pharmaceutical and biological research httpwww.ajpbr.org/ MAY-AUG (2022) 11(2):2231-2218.
  9. Ubaidova Dilafruz Saddikovna NON-invasive methodsdiagnostics of liver fibrosis in patients with diseases of the hepatobiliary system. Asian journal of Pharmaceutical and biological research httpwww.ajpbr.org/ SEPT.-DEC. (2022) 11(3):2231-2218.
  10. Ubaydova Dilafruz Saddikovna Impact of coronavirus infection (covid-19) on cardiovascular system impact of coronavirus infection on cardiovascular system. Asian journal of Pharmaceutical and biological research httpwww.ajpbr.org/ JAN.-APR. (2023) 12(1):2231-2218.
  11. Chen N., Zhou M., Dong X., et al. Epidemiological and clinical characteristics of 99 cases of (2019) novel coronavirus pneumonia inWuhan, China a descriptive study  Lancet.  (2020) 395:507-513.
  12. Cholankeril G., Podboy A., Aivaliotis V.I., et al. High prevalence of concurrent gastrointestinal manifestations in patients with SARS-CoV-2 Early Experience from Californi  Gastroenterology.  (2020) 159(2):775-777.
  13. Feng G, Zheng K.I., Yan Q.Q., Rios R.S., et al. COVID-19 and liver dysfunction current insights and emergent therapeutic strategies  J Clin Transl Hepatol.  (2020) 8(1):18-24.
  14. Guan W.J., Ni Z.Y., Hu Y., et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease (2019) in China N Engl J Med.  (2020) 382:1708-1720.
  15. Holshue M.L., Asian journal of Pharmaceutical and biological research 2231-2218 httpwww.ajpbr.org/ Universal IMPACT factor 7 SJIF MAY-AUG (2022) 11(2):465.
  16. Ronco C., Navalesi P., Vincent J.L. Coronavirus epidemic preparing for extracorporeal organ support in intensive care  Lancet Respir Med.  (2020) 8:240-241.
  17. Saigal S., Kapoor D., Sen Roy D Ademetionine in patients with liver disease a review Int J Res Med Sci.  (2019) 7(6):2482-2493.
  18. Schultz F., Hasan A., Alvarez-Laviada A., et al. The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts Prog Biophys Mol Biol.  (2016) 120(1-3):149-163.

file

download